The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old
All vaccines were immunogenic with more rapid waning after mRNA vaccines. These data support boosting with vaccines with greater specificity for circulating Omicron subvariants.
Authors
- Andrew N. J. McKenzie (ORCID: https://orcid.org/0000-0001-9757-2512)
- Marie J. Estcourt (ORCID: https://orcid.org/0000-0001-8403-6075)
- Caroline McLeod (ORCID: https://orcid.org/0000-0002-4431-3928)
- Peter Richmond (ORCID: https://orcid.org/0000-0001-7562-7228)
- Katie L. Flanagan (ORCID: https://orcid.org/0000-0002-1575-1953)
- Christopher C. Blyth (ORCID: https://orcid.org/0000-0003-2017-0683)
- Suellen R Nicholson (ORCID: https://orcid.org/0000-0001-6585-7150)
- Ushma Wadia (ORCID: https://orcid.org/0000-0002-8097-5072)
- M. Christian Tjiam
- Magdalena Plebanski (ORCID: https://orcid.org/0000-0001-6889-3667)
- R B Thornton
- Saul N. Faust (ORCID: https://orcid.org/0000-0003-3410-7642)
- Kanta Subbarao (ORCID: https://orcid.org/0000-0003-1713-3056)
- Francesca L. Mordant (ORCID: https://orcid.org/0000-0002-3754-2642)
- Helen Siobhan Marshall (ORCID: https://orcid.org/0000-0003-2521-5166)
- Zoe Ellis
- Dymock
- Thomas Snelling
- J A Marsh
Institutions
- The University of Sydney (AU)
- The University of Melbourne (AU)
- The Kids Research Institute Australia (AU)
- Peter Doherty Institute (AU)
- RMIT University (AU)
Publication Details
- Journal
- Journal of Infection
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1016/j.jinf.2024.106286
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.17